备注：
库存充足，如需更大包装，请联系销售人员，大包装有极大的折扣优惠！
详细介绍
l 基本信息 |
产品名称 | 依克立达(Elacridar) |
一般描述 | Elacridar(依克立达) is a potent P-gp (MDR-1) and BCRP inhibitor. |
别 称 | N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10H-acridine-4-carboxamide; GF120918;GG 918 |
纯 度 | ≥99%(HPLC) | CAS NO. | 143664-11-3 |
分子式 | C34H33N3O5 | 分子量 | 563.654 |
适用范围 | 生物试剂，适用于细胞培养等 |
l 理化信息 |
外 观 | 黄色固体 |
溶解性(25℃) | DMSO | ~5mg/mL |
乙醇 | Insoluble |
水 | Insoluble |
l 生物学信息 |
生物活性/药理作用 | GF120918 (Elacridar) is a very potent inhibitor of the ABC transporters MDR-1 (P-gp) and BCRP. GF120918 increases the bioavailability of cytotoxic anti-tumor drugs, and also leads to increased levels of anti-HIV drugs in the brain and CNS. Elacridar is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in of protein inhibitors. |
l 包装与存储 |
包 装 | 25mg;100mg;500mg |
存储温度 | 0-5℃ |
l 注意事项及免责声明 |
本产品仅用于实验研究，不得作为药物使用，不得用于家用或其它用途。 |
l 参考文献 |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
